BioKine $1.2M grant for new BKT140 drug

Biokine Therapeutics, Ltd. has received a $1.2 million research grant to support a Phase I/IIa clinical study to test the safety and the efficacy of the company’s flagship product, cancer drug BKT140.

In experimental models of chemotherapy treatments and bone-marrow transplants BKT140 caused the death of myeloma and leukemia cells, while encouraging the production of normal cells.

BioKine founder and CEO Dr. Amnon Peled said, “This is an exciting and significant time for the scientists, development staff, and investors who have supported the project. It is our goal to help cure and relieve the suffering of those struck by this cruel disease. Early data indicates that BKT140 may help us realize this goal."

Biokine develops pharmaceuticals that control the activity of receptors for molecules called chemokines, which play a key role in the development of cancer and inflammatory diseases.